Últimas noticias sobre Nektar Therapeutics (NASDAQ:NKTR) Bolsa

Nektar Therapeutics

Nektar Therapeutics is a pharmaceutical company focused on the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. The company is focused on discovering and developing medicines in the field of immunotherapy. Its clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases (e.g. rezpegaldesleukin and NKTR-0165, respectively) and cancer (e.g. NKTR-255).

News

NKTR

Nektar Therapeutics Announces Completion Of Target Enrollment In REZOLVE-AA Phase 2b Clinical Trial Of Rezpegaldesleukin In Patients With Severe-to-Very Severe Alopecia Areata

HC Wainwright &amp; Co. analyst Arthur He reiterates Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) with a Buy and maintains $6.5 price target.

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on Nektar Therapeutics, Maintains $6.5 Price Target

Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) and TrialNet, an international clinical trial network at the forefront of diabetes research, today announced a new collaboration agreement to evaluate Nektar's rezpegaldesleukin in patients with new onset stage 3 type 1 diabetes mellitus (T1D).
&nbsp;
Rezpegaldesleukin is a novel agonistic T regulatory (Treg) cell biologic that is designed to both dampen the inflammatory response and simultaneously restore immune balance by directly expanding functional Treg cells and engaging multiple immunoregulatory pathways. Tregs are known to play a key role in the pathogenesis of T1D.1
Under the agreement, TrialNet will conduct the Phase 2 randomized, double-blind, placebo-controlled, clinical trial to investigate the safety and potential efficacy of rezpegaldesleukin in approximately 70 adults and children with new onset stage 3 T1D. Nektar will supply rezpegaldesleukin for the trial and will provide support for the study, including pharmacokinetic and other analyses. Nektar will retain all rights to the rezpegaldesleukin program under the collaboration.

Nektar Therapeutics and TrialNet Partner to Study Rezpegaldesleukin for Type 1 Diabetes

WIIM

Nektar Therapeutics shares are trading higher after the company received Fast Track designation for Rezpegaldesleukin for the treatment of moderate-to-severe atopic dermatitis.

Biotech

Health Care

General

The FDA Has Granted Fast Track Designation To Nektar Therapeutics' Rezpegaldesleukin For Adult And Pediatric Patients 12 Years Of Age And Older With Moderate-to-severe Atopic Dermatitis Whose Disease Is Not Adequately Controlled With Topical Prescription Therapies Or When Those Therapies Are Not Advisable

<h3>Gainers</h3>
<ul>
<li>PureTech Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTC#NASDAQ">PRTC</a>) stock rose 30.9% to $25.0 during Monday's pre-market session. The market value of their outstanding shares is at $598.5 million. </li>
<li>Telix Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLX#NASDAQ">TLX</a>) shares increased by 21.88% to $22.0. The market value of their outstanding shares is at $7.3 billion. </li>
<li>Microbot Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBOT#NASDAQ">MBOT</a>) shares rose 18.43% to $3.02. The market value of their outstanding shares is at $84.6 million. </li>
<li>Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) shares rose 16.84% to $0.79. The market value of their outstanding shares is at $145.7 million. </li>
<li>Cutera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUTR#NASDAQ">CUTR</a>) shares rose 12.74% to $0.49. The company's market cap stands at $9.9 million. </li>
<li>Solid Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLDB#NASDAQ">SLDB</a>) stock increased by 12.5% to $3.24. The company's market cap stands at $129.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Pliant Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRX#NASDAQ">PLRX</a>) shares declined by 57.6% to $3.3 during Monday's pre-market session. The company's market cap stands at $200.8 million. </li>
<li>Precipio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPO#NASDAQ">PRPO</a>) stock declined by 24.87% to $5.0. The market value of their outstanding shares is at $7.4 million. </li>
<li>Replimune Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REPL#NASDAQ">REPL</a>) stock fell 19.59% to $11.21. The company's market cap stands at $862.6 million. </li>
<li>Conduit Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) shares decreased by 17.55% to $2.35. The company's market cap stands at $3.6 million. </li>
<li>Cyclo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTH#NASDAQ">CYTH</a>) shares fell 15.13% to $1.01. The market value of their outstanding shares is at $33.0 million. </li>
<li>OptiNose (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPTN#NASDAQ">OPTN</a>) stock declined by 12.05% to $5.11. The market value of their outstanding shares is at $51.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

CUTR

CYTH

MBOT

OPTN

PLRX

PRPO

PRTC

REPL

SLDB

12 Health Care Stocks Moving In Monday's Pre-Market Session

"We are pleased to announce that we reached our target enrollment for our 396-patient Phase 2b trial of rezpegaldesleukin," said Howard W. Robin, President and CEO of Nektar Therapeutics.&nbsp;
"We look forward to announcing the topline data from the 16-week induction treatment period in this study in the second quarter of 2025."
&nbsp;

Nektar Therapeutics Completes Target Enrollment In REZOLVE-AD Phase 2B Study Of Rezpegaldesleukin In Patients With Atopic Dermatitis

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Barclays analyst Paul Kearney initiated coverage on Levi Strauss &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEVI#NYSE">LEVI</a>) with an Overweight rating and announced a price target of $24. Levi Strauss shares closed at $17.67 on Tuesday. <a href="https://www.benzinga.com/quote/levi/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Truist Securities analyst Asthika Goonewardene initiated coverage on Summit Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) with a Buy rating and announced a price target of $35. Summit Therapeutics shares closed at $18.16 on Tuesday. <a href="https://www.benzinga.com/quote/SMMT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Stifel analyst Annabel Samimy initiated coverage on Altimmune, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) with a Buy rating and announced a price target of $18. Altimmune shares closed at $7.31 on Tuesday. <a href="https://www.benzinga.com/quote/alt/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B. Riley Securities analyst Mayank Mamtani initiated coverage on Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) with a Buy rating and announced a price target of $4. Nektar Therapeutics shares closed at $1.19 on Tuesday. <a href="https://www.benzinga.com/quote/nkKR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JMP Securities analyst Silvan Tuerkcan initiated coverage on Context Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTX#NASDAQ">CNTX</a>) with a Market Outperform rating and announced a price target of $4. Context Therapeutics shares closed at $1.09 on Tuesday. <a href="https://www.benzinga.com/quote/cntx/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying LEVI stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="587" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/08073956/image-46-1024x587.png" alt="" class="wp-image-723832" style="width:553px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/08073956/image-46-1024x587.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/08073956/image-46-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/08073956/image-46-768x440.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/08073956/image-46.png 1117w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/01/42846607/bank-of-new-york-mellon-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call">Bank of New York Mellon Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</a></li>
</ul>

Initiation

Pre-Market Outlook

Trading Ideas

CNTX

LEVI

SMMT

This Levi Strauss Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

B. Riley Securities analyst Mayank Mamtani initiates coverage on Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) with a Buy rating and announces Price Target of $4.

B. Riley Securities Initiates Coverage On Nektar Therapeutics with Buy Rating, Announces Price Target of $4

Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) today announced results of its Phase 2 proof-of-concept study evaluating NKTR-255 as an adjuvant treatment to enhance complete response rate (CRR) and durability following CD19-directed CAR-T therapy in patients with relapsed/refractory (R/R) Large B-cell Lymphoma (LBCL) at the 66th ASH Annual Meeting and Exposition in San Diego, California.
73% of the NKTR-255 treatment group compared to 50% of the placebo group achieved a complete response at 6 months
NKTR-255 enhanced CAR T-cell kinetics with improved CD8+ CAR-T area under the curve (AUC) 0-15 days post-administration being 5.8-fold greater than placebo-controls
&nbsp;

Nektar Therapeutics Announced NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma At ASH Meeting; 73% Of NKTR-255 Treatment Group Vs 50% Of Placebo Group Achieved Complete Response At 6 Months

- NKTR-422 demonstrated inflammation resolution and tissue repair in multiple preclinical models of chronic inflammatory conditions -
SAN FRANCISCO, Nov. 18, 2024 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) today announced its oral presentation highlighting preclinical data on NKTR-422 at the 2024 American College of Rheumatology (ACR)&nbsp;conference, being held in Washington, D.C. from November 14-19, 2024.
NKTR-422 is a novel modified&nbsp;hematopoietic colony stimulating factor (CSF) protein engineered to selectively modulate resolution processes of inflammation by targeting the expansion, reprograming and activation of anti-inflammatory tissue resident macrophages.
Currently approved inflammatory disease therapies are not designed to achieve inflammation resolution or tissue repair, which are both required for remission.1 Nektar has identified a CSF-1R agonist with a differentiated pharmacokinetic (PK)/pharmacodynamic (PD) profile compared to the native CSF-1 cytokine. Reduced clearance enables sustained PD activity from a single dose, unlike historical multiple dose per day necessary regimens of recombinant human CSF-1 administration. This CSF-1R agonist, NKTR-422, demonstrated inflammation resolution and tissue repair markers induction in tissue resident macrophages without induction of monocytosis and enhanced the efficacy of inflammatory cytokine blockade in rodent models.

Nektar Therapeutics Presents First Preclinical Data From Novel CSF-1 Program, NKTR-422, At 2024 American College Of Rheumatology  Convergence; NKTR-422 Demonstrated Inflammation Resolution And Tissue Repair In Multiple Preclinical Models Of Chronic Inflammatory Conditions

Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.22) by 18.18 percent. The company reported quarterly sales of $24.124 million which beat the analyst consensus estimate of $18.281 million by 31.96 percent. This is a 0.08 percent decrease over sales of $24.144 million the same period last year.

Earnings

Earnings Beats

Nektar Therapeutics Q3 2024 GAAP EPS $(0.18) Beats $(0.22) Estimate, Sales $24.124M Beat $18.281M Estimate

– NKTR-255 administered post completion of concurrent chemoradiation and in combination with durvalumab demonstrated statistically significant lymphocyte recovery compared to historical controls at week 8 –
– Pharmacodynamic data show NKTR-255 increased NK cell proliferation and markers of NK cell activation &nbsp;–
SAN FRANCISCO, Nov. 7, 2024 /PRNewswire/ --&nbsp;Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) and collaborators at The University of Texas MD Anderson Cancer Center today presented late-breaking results from a Phase 2 study evaluating NKTR-255 for the treatment of radiation induced lymphopenia after concurrent chemoradiation in locally advanced non-small cell lung cancer (NSCLC) patients at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting.

Nektar And Collaborators Present Late-Breaking Results From Phase 2 Study Of NKTR-255 For The Treatment Of Radiation Induced Lymphopenia In Locally Advanced Non-Small Cell Lung Cancer Patients At SITC Annual Meeting; Demonstrated Statistically Significant Lymphocyte Recovery Compared To Historical Controls At Week 8

Piper Sandler has initiated coverage on Nektar Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>), citing the company&#8217;s lead asset rezpegaldesleukin&#8217;s (REZPEG) differentiated mechanism of action.
The analyst writes that Alopecia areata (AA) is an inflammatory skin disorder where patients require lifelong use of JAK inhibitors. Thus, REZPEG&#8217;s Treg mechanism has the potential to not only restore immune privilege but also provide durable disease control and transform patient quality of life.
In August, Nektar Therapeutics said its former partner,&nbsp;Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), had presented &#8220;erroneous data&#8221; from two Phase 1b <a target="_blank" href="https://www.benzinga.com/general/biotech/23/08/33603172/why-is-nektar-therapeutics-stock-surging-today" rel="noreferrer noopener">studies of Rezpeg</a>.
In April, Nektar Therapeutics announced a strategic plan to reprioritize assets and restructure costs.
Regarding clinical programs, Nektar will prioritize the development of Rezpeg, either in collaboration with current partner Eli Lilly or&nbsp;<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/23/04/31850290/analyst-says-nektar-therapeutics-rezpeg-prioritization-likely-to-spark-investor-que" rel="noreferrer noopener">on its own in the future</a>.&nbsp;
Piper analyst writes, &#8220;Thus, by selectively stimulating Tregs, we believe REZPEG is uniquely positioned to restore immune homeostasis and mitigate the pro-inflammatory cascade across diseases&#8230;&#8221;
&#8220;REZPEG is strongly positioned to restore immune privilege and transform SoC,&#8221; the analyst adds.
Piper maintains a high probability of success for 36-week Phase 2b REZOLVE-AA n=84 Alopecia areata (AA) patients, with topline data expected in the first half of 2025.
Piper initiates with an Overweight rating and a price target of $7, an <a target="_blank" href="https://www.benzinga.com/quote/NKTR/analyst-ratings" rel="noreferrer noopener">upside of over 400%</a>.
Price Action: NKTR stock is up 10.2% at $1.355 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/11/41718169/eni-completes-1-billion-alaska-asset-sale-fast-tracks-portfolio-goal-details" target="_blank" rel="noreferrer noopener">Eni Completes $1 Billion Alaska Asset Sale, Fast-Tracks Portfolio Goal: Details</a></li>
</ul>

Analyst Color

Equities

Eczema Drug Developer Nektar Gains Analyst Confidence With 400% Upside Potential

Nektar Therapeutics shares are trading higher after the company announced it will sell its commercial PEGylation reagent manufacturing business to Ampersand Capital Partners.

Asset Sales

Nektar Therapeutics To Sell Its Commercial PEGylation Reagent Manufacturing Business To Ampersand Capital Partners For $90M Total Consideration, Comprised Of $70M In Cash and $20M Equity Ownership In New Portfolio Company

<h3>Gainers</h3>
<ul>
<li>Recursion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) stock moved upwards by 4181.6% to $274.02 during Monday's pre-market session. The market value of their outstanding shares is at $79.8 billion. </li>
<li>CVRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVRX#NASDAQ">CVRX</a>) stock increased by 8.88% to $14.59. The company's market cap stands at $316.7 million. As per the press release, Q3 earnings came out 4 days ago. </li>
<li>RAPT Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAPT#NASDAQ">RAPT</a>) shares moved upwards by 8.07% to $2.41. The market value of their outstanding shares is at $84.1 million. </li>
<li>Palatin Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PTN#AMEX">PTN</a>) stock rose 5.0% to $1.26. The company's market cap stands at $24.6 million. </li>
<li>Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) shares moved upwards by 4.87% to $1.29. The market value of their outstanding shares is at $237.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) stock fell 14.9% to $0.37 during Monday's pre-market session. The company's market cap stands at $2.6 million. </li>
<li>TG Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGTX#NASDAQ">TGTX</a>) stock declined by 13.02% to $23.4. The market value of their outstanding shares is at $3.6 billion. As per the press release, Q3 earnings came out today. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) stock declined by 7.64% to $0.06. The market value of their outstanding shares is at $3.4 million. </li>
<li>Tharimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THAR#NASDAQ">THAR</a>) stock declined by 6.7% to $2.51. The company's market cap stands at $2.8 million. </li>
<li>Verrica Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRCA#NASDAQ">VRCA</a>) stock declined by 5.23% to $1.45. The company's market cap stands at $61.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CVRX

RAPT

RXRX

TGTX

THAR

VERO

VRCA

10 Health Care Stocks Moving In Monday's Pre-Market Session

Piper Sandler analyst Yasmeen Rahimi initiates coverage on Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) with a Overweight rating and announces Price Target of $7.

Piper Sandler Initiates Coverage On Nektar Therapeutics with Overweight Rating, Announces Price Target of $7

- Data from multiple Phase 1b studies in inflammatory skin conditions demonstrate durable dose-dependent improvements in physician-assessed disease activity and patient-reported outcomes -
- Biomarker analyses demonstrate plurality of Treg-mediated pathways with potential effect on tissue resident memory T cell populations resulting in sustained efficacy seen in the antigen challenged mouse model and in clinical trials -
SAN FRANCISCO, Oct. 29, 2024 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>), today announced the publication of peer-reviewed data from two Phase 1b studies in Nature Communications highlighting the efficacy, safety, and tolerability of rezpegaldesleukin in patients with atopic dermatitis (AD) and psoriasis (PsO).
 &nbsp;

Data From Nektar's Multiple Phase 1b Studies In Inflammatory Skin Conditions Demonstrate Durable Dose-dependent Improvements In Physician-assessed Disease Activity And Patient-reported Outcomes

Press Releases

Nektar Therapeutics to Participate in Upcoming Investor Conferences

Nektar and Collaborators Present Late-breaking Results from Phase 2 Study of NKTR-255 for the Treatment of Radiation Induced Lymphopenia in Locally Advanced Non-Small Cell Lung Cancer Patients at Society for Immunotherapy of Cancer (SITC) Annual Meeting

Nektar Therapeutics Reports Third Quarter 2024 Financial Results

Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence

Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting

Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AD Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Moderate-to-Severe Atopic Dermatitis

Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis

Contracts

Nektar Announces Clinical Trial Agreement to Evaluate Rezpegaldesleukin in Patients with New Onset Type 1 Diabetes Mellitus

Nektar Therapeutics to Host Virtual Investor & Analyst Event with Type 1 Diabetes Experts on February 24th

Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AA Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Severe-to-Very Severe Alopecia Areata

Comments

Nektar Therapeutics

Noticias

Últimas noticias sobre Nektar Therapeutics (NASDAQ:NKTR) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL